InvestorPlace - Stock Market News, Stock Advice & Trading Tips
FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment.
The post Why Is FibroGen (FGEN) Stock Down 44% Today? appeared first on InvestorPlace.
More From InvestorPlace